POS-831 THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH eGFR <30 mL/min/1.73m2: FINDINGS FROM THE DAPA-CKD TRIAL

Autor:	David C. Wheeler, Ricardo Correa-Rotter, Fan Fan Hou, Niels Jongs, Bergur V. Stefánsson, John J.V. McMurray, H. Lambers Heerspink, R D Toto, AM Langkilde, Priya Vart, C. D. Sjöström, Glenn M. Chertow, Peter Rossing, José Luis Górriz
Rok vydání:	2021
Předmět:	chemistry.chemical_compound medicine.medical_specialty chemistry Nephrology business.industry Urology medicine In patient RC870-923 Dapagliflozin business Diseases of the genitourinary system. Urology
Zdroj:	Kidney International Reports, Vol 6, Iss 4, Pp S361-S362 (2021)
ISSN:	2468-0249
DOI:	10.1016/j.ekir.2021.03.869
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc68886349bae45ab483801ca5175ebf https://doi.org/10.1016/j.ekir.2021.03.869 Zobrazit plný text záznamu